Abstract
We report the first case of teriparatide adjuvant role in the management of a denosumab-induced osteonecrosis of the jaw in a male subject with idiopathic osteoporosis. Clinical benefits and CT healing were obtained within 2 months of teriparatide initiation and denosumab withdrawal. Increase in bone turnover previously described, when denosumab treatment is removed, might have a synergistic effect to the stimulating effect of teriparatide on bone remodeling to promptly heal osteonecrosis of the jaw. © 2014 Springer Science+Business Media.
Author supplied keywords
Cite
CITATION STYLE
Neuprez, A., Rompen, E., Crielaard, J. M., & Reginster, J. Y. (2014). Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient. Calcified Tissue International, 95(1), 94–96. https://doi.org/10.1007/s00223-014-9858-3
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.